Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes.

ABSTRACT: Dapagliflozin is associated with greater reductions in HbA1c and weight than saxagliptin in management of type 2 diabetes mellitus (T2DM). The present post hoc analyses compared the durability of these effects over short- and long-term follow-up in patients with T2DM who were inadequately controlled with metformin (?1500?mg/day) and who were receiving either dapagliflozin (10 mg/day) or saxagliptin (5 mg/day). Failure of glycaemiccontrol was assessed using the slope of the change in HbA1c from baseline-over-time regression line (coefficient of failure [CoF]). CoF was compared directly (dapagliflozin vs saxagliptin) over the short term (NCT01606007, 24?weeks) and indirectly (placebo-adjusted) over the long term (NCT00528879 and NCT00121667, 102?weeks). A low CoF value indicated greater durability. CoF was lower for dapagliflozin versus saxagliptin over 18-24?weeks (-1.38%/year; 95% CI, -2.41 to -0.35; P =?.009) and 20-102?weeks (-0.37%/year; 95% CI, -0.73 to -0.02; P =?.04). Fewer dapagliflozin-treated patients versus saxagliptin-treated patients required rescue medication or discontinued the study because of failure to achieve glycaemic control at 24?weeks (3.4% vs 9.4%; P =?.0191). In patients with T2DM who were inadequately controlled with metformin, dapagliflozin was associated with greater durability of glycaemic control than saxagliptin over 18-24 and 20-102?weeks.

SUBMITTER: Bailey CJ 

PROVIDER: S-EPMC6851837 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature